Rheinmetall’s Recovery Rhythm: Artillery Contracts and Medical Missions Offset a Frigate Shock

Rheinmetall surges 16% after Ukraine shell and Morocco hospital deals, rebounding from 19% plunge. Still down 31% YTD, technicals show caution.

Rheinmetall’s stock suffered a near-19% plunge on 24 June when German Defence Minister Boris Pistorius unexpectedly scrapped a frigate-building programme, wiping billions of euros in potential order value. Yet the shares have staged a remarkable comeback, buoyed by two new contracts — one for Ukrainian artillery shells and another for mobile field hospitals in Morocco — that underscore the group’s push beyond its core naval business.

The larger of the two deals comes from Kyiv: a low-five-digit order for 155mm artillery shells, valued in the high double-digit million-euro range. Rheinmetall will book the revenue retroactively in the second quarter of 2026, with production already under way at its Spanish subsidiary Expal Munitions. Delivery is scheduled for completion by early 2027. The order fits neatly into the group’s broader capacity push — it aims to produce roughly 1.5 million large-calibre units annually by 2030. That long-term outlook has helped lure buyers back, lifting the stock 16.37% on a weekly basis to close at €1,094.60 on Friday.

The Morocco contract, though smaller, illustrates the group’s broadening product mix. Rheinmetall’s Mobile Systeme GmbH subsidiary has signed a deal to supply seven field hospitals — one for the Moroccan Defence Ministry and six for the Interior Ministry. The value sits in the mid-double-digit million range, with delivery planned for 2027 and 2028. The hospitals are based on models already deployed with the Ukrainian army, featuring a self-contained surgical block with an intensive care unit and sterilisation unit. A local medical-equipment distributor is handling the in-country logistics.

Despite these gains, the stock remains deep in the red over longer horizons. The shares hit a 52-week low of €902.50 on 25 June, from which they have recovered 21.15%. Yet year-to-date the stock is still down 31.73%, and over twelve months it has lost 35.68%. The 52-week peak of €1,995, set in September 2025, now sits 45.19% above current levels. Technical indicators flash caution: the 200-day moving average is €28.87% above the last trade, while the 50-day average of €1,197.07 remains well out of reach. Volatility remains extreme, with a 30-day annualised figure of 69.32%, and the relative strength index at 46.2 signals a neutral stance.

The broader European defence sector is also under pressure. Rival KNDS recently shelved its planned initial public offering, citing inflated valuations, and that triggered a sector-wide sell-off: Rheinmetall lost 12%, Renk dropped 13%, and Hensoldt fell 8%. The chart pattern still warns of turbulence ahead.

Investors now have two key catalysts on the horizon. For the second half of 2026, Rheinmetall is reportedly planning a joint venture with Destinus to expand into advanced missile systems. The next major test will be the half-year report due on 6 August, which must demonstrate whether the growing ammunition business can financially compensate for the frigate programme’s collapse. The Moroccan field-hospital order, while modest in scale, adds a further growth pillar — and offers a glimpse of a company shifting its revenue base one contract at a time.